Taletrectinib adipate is under clinical development by AnHeart Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Taletrectinib adipate’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 04 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Taletrectinib adipate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Taletrectinib adipate overview
Taletrectinib (DS-6051b/AB-106) is under development for the treatment of relapsed or refractory solid tumors including k-RAS wild-type colorectal cancer, neuroendocrine tumors, non-small-cell lung carcinoma (NSCLC), primary CNS tumors, brain metastases and pulmonary large-cell neuroendocrine carcinoma (LCNEC). It is administered orally as a capsule. The drug candidate targets tyrosine kinases ROS1 and NTRKs type 1, 2, 3.
AnHeart Therapeutics overview
AnHeart Therapeutics is a clinical stage biopharmaceutical company that focuses on oncology drugs to address unmet medical needs and underserved markets. The company is headquartered in New York City, New York, the US.
Quick View Taletrectinib adipate LOA Data
|Highest Development Stage|